| abstract |
It is intended to provide a biomarker for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release such as itching, and utilization of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for an intractable itching skin disease, for which the existing antiallergic drugs are little efficacious, and easily and adequately make a diagnosis of the disease. Also, it makes possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of a novel remedy for an allergic disease. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment for an allergic disease with little side effect. |